Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.
Horinouchi H.
Transl Lung Cancer Res · editorial; journal article · DOI 10.3978/j.issn.2218-6751.2015.06.08 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för linifanib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
11 träffarSimple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS.
Iqbal M, Ezzeldin E, Wani TA, Khalil NY.
Chem Cent J · research-article; journal article · DOI 10.1186/1752-153x-8-13Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells.
Hsu HW, Gridley DS, Kim PD, Hu S, de Necochea-Campion R, Ferris RL, Chen CS, Mirshahidi S.
Oral Oncol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.oraloncology.2013.02.009Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP.
Cancer · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1002/cncr.27758ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.
Jiang F, Albert DH, Luo Y, Tapang P, Zhang K, Davidsen SK, Fox GB, Lesniewski R, McKeegan EM.
J Pharmacol Exp Ther · comparative study; journal article · DOI 10.1124/jpet.110.178061ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.
Ikeda AK, Judelson DR, Federman N, Glaser KB, Landaw EM, Denny CT, Sakamoto KM.
Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-09-0812ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
Zhou J, Goh BC, Albert DH, Chen CS.
J Hematol Oncol · research support, non-u.s. gov't; review-article; review; evaluation study; journal article · DOI 10.1186/1756-8722-2-33Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
Franklin PH, Banfor PN, Tapang P, Segreti JA, Widomski DL, Larson KJ, Noonan WT, Gintant GA, Davidsen SK, Albert DH, Fryer RM, Cox BF.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.108.144816Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Harris CM, Hickman D, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Martin RL, Olson AM, Osterling DJ, Pease LJ, Soni NB, Stewart KD, Stoll VS, Tapang P, Reuter DR, Davidsen SK, Michaelides MR.
J Med Chem · journal article · DOI 10.1021/jm061280hPreclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, Niquette AL, Soni N, Johnson EF, McCall JO, Bouska JJ, Luo Y, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK.
Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-05-0410Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, Glaser KB.
Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-05-0359